From Université Paris-Descartes, INSERM UMR 894, Department of Neuroradiology (A.L., C.R.R., F.A.S., D.T., S.G.H., W.B.H., J.F.M., C.O., O.N.N.), Centre Hospitalier Sainte-Anne, Paris and the International Consortium of Neuroendovascular Centres, Interventional Neuroradiology Research Unit, Department of Radiology, University of Montreal, CHUM Notre-Dame Hospital, Montreal, QC, Canada (J.R.).
Radiology. 2015 Oct;277(1):173-80. doi: 10.1148/radiol.2015142496. Epub 2015 Jun 9.
To assess the efficacy of endovascular treatment (EVT) of intracranial aneurysms for recurrence, bleeding, and de novo aneurysm formation at long-term follow-up (> 10 years after treatment) with magnetic resonance (MR) angiography and to identify risk factors for recurrence through a prospective study and a systematic review of the literature.
Clinical examinations and 3-T MR angiography were performed prospectively 10 years after EVT of intracranial aneurysms in a single institution. Ethics committee approval and informed consent were obtained. PubMed, EMBASE, and Cochrane databases were searched to identify studies in which authors reported bleeding and/or aneurysm recurrence rates in patients who received follow-up more than 10 years after EVT. Univariate and multivariate subgroup analyses were performed to identify risk factors (midterm MR angiographic results, aneurysm characteristics, retreatment within 5 years).
In the prospective study, sac recanalization occurred between midterm and long-term MR angiography in 16 of 129 (12.4%) aneurysms. Grade 2 classification on the Raymond scale at midterm MR angiography (relative risk [RR], 4.16; 99% confidence interval [CI]: 2.12, 8.14) and retreatment within 5 years (RR, 4.67; 99% CI: 1.55, 14.03) were risk factors for late recurrence. In the systematic review (15 cohorts, 2773 patients, 2902 aneurysms), bleeding, aneurysm recurrence, and de novo lesion formation rates were, respectively, 0.7% (99% CI: 0.2%, 2.7%; I(2), 0%; one of 694 patients), 11.4% (99% CI: 7.0%, 18.0%; I(2), 21.6%), and 4.1% (99% CI: 1.7, 9.4%; I(2), 54.1%). Raymond grade 2 initial result (RR, 7.08; 99% CI: 1.24, 40.37; I(2), 82.6%) and aneurysm size greater than 10 mm (RR, 4.37; 99% CI: 1.83, 10.44; I(2), 0%) were risk factors for late recurrence.
EVT of intracranial aneurysm is effective for prevention of long-term bleeding, but recurrences occur in a clinically relevant percentage of patients, a finding that may justify follow-up of selected patients for 10 years or more, such as patients with aneurysms larger than 10 mm or classified as Raymond grade 2 at midterm MR angiography.
通过前瞻性研究和对文献的系统回顾,使用磁共振(MR)血管造影评估颅内动脉瘤血管内治疗(EVT)后 10 年以上的复发、出血和新形成的动脉瘤的疗效,并确定复发的危险因素。
在一家机构内对颅内动脉瘤 EVT 后 10 年进行临床检查和 3-T MR 血管造影。获得伦理委员会批准和知情同意。在 PubMed、EMBASE 和 Cochrane 数据库中搜索,以确定作者在 EVT 后随访超过 10 年的患者中报告出血和/或动脉瘤复发率的研究。进行单变量和多变量亚组分析,以确定危险因素(中期 MR 血管造影结果、动脉瘤特征、5 年内再次治疗)。
在前瞻性研究中,129 个动脉瘤中有 16 个(12.4%)在中期和长期 MR 血管造影之间出现囊再通。中期 MR 血管造影时 Raymond 分级 2 级(相对风险 [RR],4.16;99%置信区间 [CI]:2.12,8.14)和 5 年内再次治疗(RR,4.67;99%CI:1.55,14.03)是晚期复发的危险因素。在系统评价(15 个队列,2773 例患者,2902 个动脉瘤)中,出血、动脉瘤复发和新发病变的发生率分别为 0.7%(99%CI:0.2%,2.7%;I²,0%;694 例患者中有 1 例)、11.4%(99%CI:7.0%,18.0%;I²,21.6%)和 4.1%(99%CI:1.7%,9.4%;I²,54.1%)。初始 Raymond 分级 2 级结果(RR,7.08;99%CI:1.24,40.37;I²,82.6%)和动脉瘤大小大于 10mm(RR,4.37;99%CI:1.83,10.44;I²,0%)是晚期复发的危险因素。
颅内动脉瘤 EVT 对预防长期出血有效,但在临床相关比例的患者中会出现复发,这一发现可能证明对某些患者进行 10 年或更长时间的随访是合理的,例如动脉瘤直径大于 10mm 或中期 MR 血管造影时 Raymond 分级为 2 级的患者。